Former Chief Operating Officer, President of R&D and Product Operations · Revance Therapeutics, Inc. (RVNC)

Abhay Joshi

A named executive officer of Revance Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$3,260,376

Salary $209,901Stock awards $309,543

FY2021: $2,586,759

2nd of 5 named executive officers at Revance Therapeutics by FY2022 total.

5 named officers on file for Revance Therapeutics, FY2022

Abhay Joshi’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 14 equity grants, each cited to its filing
  • RVNC’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Revance Therapeutics’s whole pay program stands against its peers

  • Revance Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RVNC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 23, 2023 (DEF 14A).

Free

Get Abhay Joshi’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Abhay Joshi compensation by year

Revance Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Revance Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022
Salary$485,479$514,608$519,754$209,901
Bonus$0$0$0$0
Stock awards$271,373$1,405,850$1,267,172$309,543
Option awards$939,314$1,913,759$634,014$2,309,087
Non-equity incentive$204,211$213,726$154,081$0
Pension and deferred compensation$0$0$0$0
All other$9,520$11,731$11,738$431,845
Total$1,909,897$4,059,674$2,586,759$3,260,376

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Revance Therapeutics, Inc. DEF 14A filed March 23, 2023, accession 0001479290-23-000049, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Revance Therapeutics, Inc. filed document, accession 0001479290-23-000049. Every figure is read from that document and cited to the page and table it appears in. Filed March 23, 2023.

$1.9M
$4.1M
$2.6M
$3.3M
FY19
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU22,620$417,565—
PSU20,000$369,200—
RSU15,080$278,377—
RSU8,334$153,846—
Option39,678—$22.32
Option1,959—$17.23
Option22,168—$28.01

Per the Outstanding Equity Awards at Fiscal Year-End table in Revance Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Revance Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Mark FoleyChief Executive Officer$6,606,916
Abhay Joshi · this pageFormer Chief Operating Officer, President of R&D and Product Operations$3,260,376
Dustin SjutsPresident$2,592,449
Tobin SchilkeChief Financial Officer$2,279,831
Dwight MoxieSenior Vice President, General Counsel and Corporate Secretary$2,269,921

The full Revance Therapeutics compensation record

free company brief

This page is one person within Revance Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Revance Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Revance Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Abhay Joshi's compensation dossier · One-time report. No refunds.